



CLINUVEL

Mr James Gerraty
Manager Listings, Melbourne
Level 45, Rialto South Tower
525 Collins Street, Melbourne VIC 3000

22 June 2018

Via email

Re: **REQUEST FOR TRADING HALT**

Dear Mr Gerraty,

Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV) requests an immediate trading halt with respect to its ordinary shares listed on the ASX.

The trading halt is necessary as CUV proposes to make an announcement to the market regarding a regulatory submission for its drug SCENESSE®.

CUV requests that trading in its securities be halted until after the expected announcement is made or until the commencement of trade on Tuesday 26th June 2018, whichever is the earlier.

CUV is not aware of any reason why the trading halt should not be granted by the ASX nor is it aware of any other information that is necessary to inform the market about the trading halt.

Yours faithfully,

Darren Keamy
Chief Financial Officer &
Company Secretary
CLINUVEL PHARMACEUTICALS LTD

Australian Office: Level 6, 15 Queen Street, Melbourne, Victoria 3000, Australia. T +61 3 9660 4900

Swiss Office: Zugerstrasse 76a, 6340 Baar, Switzerland. T +41 (0)41 763 17 82

US Office: PO BOX 7388, Menlo Park, CA 94026, USA

UK Office: Wesley House, Bull Hill, Leatherhead, Surrey, KT22 7AH, United Kingdom. T +44 1372 860 765

www.clinuvel.com